Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2013 | 03:34am CET

The Burzynski Clinic (BC) announced today that it made a keynote speaker presentation at the 2nd Annual Congress of Asia-Pacific Academy of Anti-Aging Medicine in Beijing, China. Based on the presentation in Beijing, a total of 401 eligible patients (patients who received over 28 days of treatment) with advanced inoperable brain tumors have been treated with antineoplaston A10 and antineoplastons AS2-1 therapy (ANP) in phase II studies. Most of the patients (87%) were diagnosed with high-grade tumors and the remaining patients were diagnosed with low-grade tumors. The patients were diagnosed by pathologists not associated with BC and objective responses were verified by Central Radiology Review. The group of 77 patients (19%) survived over five years from the treatment start. Of particular interest were results in patients with brainstem gliomas. The group of 17 patients with brainstem glioma underwent the treatment and 65% of these patients survived over five years. An additional group of 42 patients diagnosed with diffuse intrinsic pontine glioma (DIPG) have been treated and a total of 19% survived over five years.

The quality of survival is very good and there is no long-term toxicity related to ANP.

These clinical results are very encouraging, since they describe a positive ANP effect on some of the worst malignancies in the entire oncology field, but they will require FDA approval.

Burzynski Clinic is committed to developing treatments for cancer based on genomic and epigenomic principles.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic's ability to use Antineoplastons A10 and AS2-1. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.

For Burzynski Clinic
Carolyn Powers, 713-335-5664
carolyn@burzynskiclinic.com


© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
09:12p ALEXION PHARMACEUTICALS, INC. : Khang & Khang LLP Announces Securities Class Action Lawsuit against Alexion Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
09:11p Stop Paying for Unused Parking Time! B-CITI's New Generation App, Launched in Sherbrooke Today, Revolutionizes Parking Transactions
09:10p Trump vows to bring down drug prices, doesn't say how
09:10p COMCAST 2CPS29 : Tupelo council delays action on Comcast agreement
09:09p AGRIA CORPORATION (ADR) : Khang & Khang LLP Announces Securities Class Action Lawsuit against Agria Corporation and Encourages Investors with Losses to Contact the Firm
09:08p Oil slips on bearish U.S. inventory report, doubts over OPEC cut
09:08p Fitch Affirms Kinder Morgan, Inc. and Subs at 'BBB-'; Outlook Stable
09:08p TEGNA : Provides Comprehensive Update, 2017 Outlook at UBS Global Media and Communications Conference
09:08p AMMONIUM SULPHATE MARKET IN POLAND : 2010-2020 Review - Research and Markets
09:07p Oil slips on bearish U.S. inventory report, doubts over OPEC cut
Latest news
Advertisement
Hot News 
-11.79%VERA BRADLEY : Shares Drop as Company Slashes Outlook
14.66%SUNPOWER : CEO expects solar panel prices decline to stop next year
-3.90%CARILLION : sees slowdown in pace of new orders post-Brexit
1.34%WALL STREET STOCK EXCHANGE : Dow, S&P hit highs; Trump comment hammers drug stocks
9.45%STEINHOFF INTERNATIONAL : Poundland shifts away from one price fits all
Most Read News
12/06 SAMSUNG ELECTRONICS : U.S. Supreme Court backs Samsung in smartphone fight with Apple
06:57a Sony to release six smartphone games to accelerate mobile drive
01:52a EXCLUSIVE : In mammoth task, BP sends almost three million barrels of U.S. oil to Asia
09:58a TSX rises to 18-month high ahead of Bank of Canada
02:33a BANCA MONTE DEI PASCHI DI SIENA : Italy set to ask ESM 15 billion euros for banking sector - report
Most recommended articles
12/02 Platts considers first addition to Brent basket since 2007
11/30DJCash Crunch Looms Over India's Growth Spurt
03:06pDJShell Signs Preliminary Iran Oil Deal Despite Trump Doubts
03:05p WOLFGANG REITZLE : Linde resumes merger talks with Praxair, CEO resigns
03:05pDJNIKE HYPERADAPT 1.0 SELF-LACING SNEAKER : A Highly Skeptical Road Test